Last reviewed · How we verify
SRT501
At a glance
| Generic name | SRT501 |
|---|---|
| Sponsor | Sirtris, a GSK Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study). (NA)
- Resveratrol-Based Gel Application in a Palatal Wound Following Free Gingival Graft Surgery (NA)
- A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes (NA)
- Resveratrol for the Prevention of Bone Loss in Postmenopausal Women (NA)
- Resveratrol in Knee Osteoarthritis (PHASE3)
- Supplementation With Sirtuin Activators in Women With Increased Body Weight (NA)
- Resveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters. (NA)
- Clinical and Laboratory Evaluation of Resveratrol Loaded Nanoparticles in the Treatment of Periodontitis: A Randomized Controlled Clinical Trial (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SRT501 CI brief — competitive landscape report
- SRT501 updates RSS · CI watch RSS
- Sirtris, a GSK Company portfolio CI